Trials / Not Yet Recruiting
Not Yet RecruitingNCT07463183
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants With Moderately to Severely Active Ulcerative Colitis
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8690 | Solution for subcutaneous injection |
| OTHER | Placebo | Solution for subcutaneous injection |
Timeline
- Start date
- 2026-03-30
- Primary completion
- 2027-10-28
- Completion
- 2028-12-21
- First posted
- 2026-03-11
- Last updated
- 2026-03-30
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07463183. Inclusion in this directory is not an endorsement.